Latest 20-F annual reports

Altamira Therapeutics focuses on RNA delivery technology, divesting non-core assets and reporting its annual results in a Form 20-F filing.

ATA Creativity Global provides a description of its American Depositary Shares (ADSs) and the rights of holders in its latest filing.

NewGenIvf Group Limited files its 20-F report, detailing the completion of its business combination and providing information on its operations and financial condition.

Cognyte Software Ltd. releases its annual report on Form 20-F, detailing its financial performance and operational activities for the fiscal year ended January 31, 2024.

Jianzhi Education Technology Group's 20-F filing outlines the rights of security holders and provides financial details for the year ended December 31, 2023.

NIO Inc. finalizes a \$2.2 billion share subscription agreement with CYVN Investments RSC Ltd, bolstering its financial position.

Mainz Biomed N.V. files its annual report on Form 20-F, outlining its business strategy, financial performance, and risk factors, with a focus on expanding its ColoAlert product in Europe and entering the U.S. market.

Medicure Inc.'s 2023 results reveal a decrease in AGGRASTAT sales due to generic competition, offset by growth in Marley Drug's revenue.

DigiAsia Corp., formerly StoneBridge Acquisition Corporation, successfully consummated its business combination on April 2, 2024, and began trading on the Nasdaq Capital Market under the symbols FAAS and FAASW on April 3, 2024.

Siyata Mobile Inc.'s 20-F filing reveals a history of operating losses and substantial doubt about its ability to continue as a going concern, despite a revenue increase in 2023.

Biophytis S.A. releases its 20-F filing, detailing financial results, ongoing clinical programs, and future strategies in the biotechnology sector.

Nano Labs Ltd.'s 2023 annual report reveals a net loss, decreased revenue due to cryptocurrency market shifts, and ongoing efforts to expand into overseas markets and new technologies.

CLPS Incorporation filed an amendment to its 20-F annual report to address SEC comments regarding disclosures related to foreign jurisdictions that prevent inspections.

Perion Network Ltd. releases its 20-F annual report, detailing financial results and outlining key business strategies for the year ended December 31, 2023.

International General Insurance Holdings Ltd. details executive employment agreements, compensation structures, and corporate governance policies in a recent SEC filing.

RedHill Biopharma reports net income for 2023 but acknowledges substantial doubt about its ability to continue as a going concern due to insufficient working capital.

Luckin Coffee ends contractual agreements with its former variable interest entity (VIE) to optimize corporate governance.

Hitek Global Inc. releases its annual report on Form 20-F, providing insights into its financial results, corporate structure, and risk factors for the year ended December 31, 2023.

Abivax outlines the terms and conditions of its outstanding share warrant and free share plans as of January 1, 2024.

GENFIT's recent filing details the structure and terms of its equity incentive plans, including stock options and free shares, aimed at aligning employee and executive interests with company performance.

Eni SpA's 20-F filing provides a comprehensive overview of the company's financial results, strategic direction, and key operational activities, highlighting its commitment to a just energy transition and sustainable development.

Zegna Group's 2023 20-F filing reveals key financial data, strategic shifts, and risk assessments for the luxury fashion conglomerate.

Vision Marine Technologies files an amendment to its annual report to reflect that the consolidated financial statements were audited, not unaudited.

Embraer's 20-F filing details the company's financial performance, strategic initiatives, and risk factors for the fiscal year ended December 31, 2023.

Diana Shipping Inc. finalizes a $100 million term loan facility to refinance existing debt and for general corporate purposes.

Galmed Pharmaceuticals reports a reduced net loss for 2023 and outlines its strategic focus on developing Aramchol for Primary Sclerosing Cholangitis (PSC).

NeuroSense Therapeutics' 20-F filing highlights clinical trial progress, financial status, and key risk factors for investors.

Lichen China Limited's 20-F filing details director compensation, corporate structure, and potential risks including those related to doing business in China.

Kelso Technologies Inc. announces its fiscal year 2023 results, highlighting challenges in the rail market and progress in automotive technology development.

Achilles Therapeutics extends a manufacturing agreement with Cell and Gene Therapy Catapult and files its annual report on Form 20-F with the SEC.